Niosomal delivery of simvastatin to MDA-MB-231 cancer cells

References

• Shuhaili M, Samsudin IN, Stanslas J, et al. Effects of different types of statins on lipid profile: a perspective on Asians. Int J Endocrinol Metab. 2017;15(2):e43319.
   PubMed Web of Science ®Google Scholar
• Afzali M, Vatankhah M, Ostad SN. Investigation of simvastatin-induced apoptosis and cell cycle arrest in cancer stem cells of MCF-7. J Can Res Ther. 2016;12(2):725.
   PubMed Web of Science ®Google Scholar
• Wang T, Seah S, Loh X, et al. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 2016;7(3):2532–2544.
   PubMedGoogle Scholar
• Shen YY, Yuan Y, Du YY, et al. Molecular mechanism underlying the anticancer effect of simvastatin on MDA-MB-231 human breast cancer cells. Mol Med Rep. 2015;12(1):623–630.
   PubMed Web of Science ®Google Scholar
• Jiang P, Mukthavaram R, Chao Y, et al. In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer. 2014;111(8):1562–1571.
   PubMed Web of Science ®Google Scholar
• Buranrat B, Suwannaloet W, Naowaboot J. Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells. Oncol Lett. 2017;14(5):6243–6250.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–430.
   PubMed Web of Science ®Google Scholar
• Ahern TP, Lash TL, Damkier P, et al. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 2014;15(10):e461–e468.
   PubMed Web of Science ®Google Scholar
• Matusewicz L, Meissner J, Toporkiewicz M, et al. The effect of statins on cancer cells—review. Tumour Biol. 2015;36(7):4889–4904.
   PubMedGoogle Scholar
• Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, et al. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal. 2010;22(5):749–758.
   PubMed Web of Science ®Google Scholar
• Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Ther Adv Drug Saf. 2012;3(3):133–144.
   PubMedGoogle Scholar
• Petyaev IM. Improvement of hepatic bioavailability as a new step for the future of statin. Arch Med Sci. 2015;11(2):406–410.
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117–125.
   PubMed Web of Science ®Google Scholar
• Ge X, Wei M, He S, et al. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics. 2019;11(2):55.
   PubMed Web of Science ®Google Scholar
• Tran TT, Tran PH. Nanoconjugation and encapsulation strategies for improving drug delivery and therapeutic efficacy of poorly water-soluble drugs. Pharmaceutics. 2019;11(7):325.
   Web of Science ®Google Scholar
• Rabiee N, Yaraki MT, Garakani SM, et al. Recent advances in porphyrin-based nanocomposites for effective targeted imaging and therapy. Biomaterials. 2020;232:119707.
   PubMed Web of Science ®Google Scholar
• Tayebi M, Yaraki MT, Mogharei A, et al. Thioglycolic acid-capped CdS quantum dots conjugated to α-amylase as a fluorescence probe for determination of starch at low concentration. J Fluoresc. 2016;26(5):1787–1794.
   PubMed Web of Science ®Google Scholar
• Tayebi M, Yaraki MT, Ahmadieh M, et al. Synthesis, surface modification and optical properties of thioglycolic acid-capped ZnS quantum dots for starch recognition at ultralow concentration. J Electron Mater. 2016;45(11):5671–5678.
   Web of Science ®Google Scholar
• Yaraki MT, Rezaei SD, Tan YN. Simulation guided design of silver nanostructures for plasmon-enhanced fluorescence, singlet oxygen generation and SERS applications. Phys Chem Chem Phys. 2020;22(10):5673–5687.
   PubMed Web of Science ®Google Scholar
• Tayebi M, Yaraki MT, Yang HY, et al. A MoS2–MWCNT based fluorometric nanosensor for exosome detection and quantification. Nanoscale Adv. 2019;1(8):2866–2872.
   Web of Science ®Google Scholar
• Shad PM, Karizi SZ, Javan RS, et al. Folate conjugated hyaluronic acid coated alginate nanogels encapsulated oxaliplatin enhance antitumor and apoptosis efficacy on colorectal cancer cells (HT29 cell line). Toxicol In Vitro. 2020;65:104756.
   PubMed Web of Science ®Google Scholar
• Lajevardi A, Sadr MH, Yaraki MT, et al. A pH-responsive and magnetic Fe3O4@silica@ MIL-100 (Fe)/β-CD nanocomposite as a drug nanocarrier: loading and release study of cephalexin. New J Chem. 2018;42(12):9690–9701.
   Web of Science ®Google Scholar
• Buchiraju R, Nama S, Sakala B, et al. Vesicular drug delivery system – an overview. Res J Pharm Biol Chem Sci. 2014;4(3):462.
   Google Scholar
• Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5(5):442–453.
   PubMed Web of Science ®Google Scholar
• Ghafelehbashi R, Yaraki MT, Saremi LH, et al. A pH-responsive citric-acid/α-cyclodextrin-functionalized Fe3O4 nanoparticles as a nanocarrier for quercetin: an experimental and DFT study. Mater Sci Eng C. 2020;109:110597.
   PubMed Web of Science ®Google Scholar
• Shirzad M, Jamehbozorgi S, Akbarzadeh I, et al. The role of polyethylene glycol size in chemical spectra, cytotoxicity, and release of PEGylated nanoliposomal cisplatin. Assay Drug Dev Technol. 2019;17(5):231–239.
   PubMed Web of Science ®Google Scholar
• Safwat S, Hathout RM, Ishak RA, et al. Augmented simvastatin cytotoxicity using optimized lipid nanocapsules: a potential for breast cancer treatment. J Liposome Res. 2017;27(1):1–10.
   PubMed Web of Science ®Google Scholar
• Khan R, Irchhaiya R. An overview on niosomes as efficient drug carriers. Int J Pharm Biosci. 2017;8:106–116.
   Google Scholar
• Muzzalupo R, Tavano L. Niosomal drug delivery for transdermal targeting: recent advances. Res Rep Transderm Drug Deliv. 2015;4:23–33.
   Google Scholar
• Khindri S, Aggarwal G, Hari Kumar SL. Role of niosomes and proniosomes for enhancing bioavailability of drugs. J Drug Deliv Ther. 2015;5(1):28–33.
   Google Scholar
• Akbarzadeh I, Fatemizadeh M, Heidari F. Niosomal formulation for co-administration of hydrophobic anticancer drugs into MCF-7 cancer cells. Arch Adv Biosci. 2020;11(2).
   Google Scholar
• Dharashivkar S, Sahasrabuddhe S, Saoji A. Silver sulfadiazine niosomes: a novel sustained release once a day formulation for burn treatment. Int J Pharm Pharm Sci. 2014;6(1):611–616.
   Google Scholar
• Agarwal S, Mohamed MS, Raveendran S, et al. Formulation, characterization and evaluation of morusin loaded niosomes for potentiation of anticancer therapy. RSC Adv. 2018;8(57):32621–32636.
   PubMed Web of Science ®Google Scholar
• Ghafelehbashi R, Akbarzadeh I, Yaraki MT, et al. Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Int J Pharm. 2019;569:118580.
   PubMedGoogle Scholar
• Nasseri B. Effect of cholesterol and temperature on the elastic properties of niosomal membranes. Int J Pharm. 2005;300(1–2):95–101.
   PubMed Web of Science ®Google Scholar
• Moghassemi S, Parnian E, Hakamivala A, et al. Uptake and transport of insulin across intestinal membrane model using trimethyl chitosan coated insulin niosomes. Mater Sci Eng C Mater Biol Appl. 2015;46:333–340.
   PubMed Web of Science ®Google Scholar
• Mehta SK, Jindal N, Kaur G. Quantitative investigation, stability and in vitro release studies of anti-TB drugs in Triton niosomes. Colloids Surf B Biointerfaces. 2011;87(1):173–179.
   PubMed Web of Science ®Google Scholar
• Sadeghi S, Ehsani P, Cohan RA, et al. Design and physicochemical characterization of lysozyme loaded niosomal formulations as a new controlled delivery system. Pharm Chem J. 2020;53(10):921–930.
   Web of Science ®Google Scholar
• Dash S, Murthy PN, Nath L, et al. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–223.
   PubMed Web of Science ®Google Scholar
• Kamboj S, Saini V, Bala S. Formulation and characterization of drug loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement. Sci World J. 2014;2014:1–8.
   Web of Science ®Google Scholar
• Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech. 2010;11(3):1119–1127.
   PubMed Web of Science ®Google Scholar
• Rochdy Haj-Ahmad R, Ali Elkordy A, Shu Chaw C. In vitro characterisation of Span 65 niosomal formulations containing proteins. Curr Drug Deliv. 2015;12(5):628–639.
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Ismail S, Kamal A, et al. Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. J Pharm Sci. 2011;100(5):1833–1846.
   PubMed Web of Science ®Google Scholar
• Li Q, Li Z, Zeng W, et al. Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur J Pharm Sci. 2014;62:115–123.
   PubMed Web of Science ®Google Scholar
• Basiri L, Rajabzadeh G, Bostan A. α-Tocopherol-loaded niosome prepared by heating method and its release behavior. Food Chem. 2017;221:620–628.
   PubMed Web of Science ®Google Scholar
• Shaker DS, Shaker MA, Hanafy MS. Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes. Int J Pharm. 2015;493(1–2):285–294.
   PubMed Web of Science ®Google Scholar
• Kassem MA, El-Sawy HS, Abd-Allah FI, et al. Maximizing the therapeutic efficacy of imatinib mesylate-loaded niosomes on human colon adenocarcinoma using Box-Behnken design. J Pharm Sci. 2017;106(1):111–122.
   PubMed Web of Science ®Google Scholar
• Patel J, Ketkar S, Patil S, et al. Potentiating antimicrobial efficacy of propolis through niosomal-based system for administration. Integr Med Res. 2015;4(2):94–101.
   PubMed Web of Science ®Google Scholar
• Bragagni M, Mennini N, Furlanetto S, et al. Development and characterization of functionalized niosomes for brain targeting of dynorphin-B. Eur J Pharm Biopharm. 2014;87(1):73–79.
   PubMed Web of Science ®Google Scholar
• Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22–36.
   PubMed Web of Science ®Google Scholar
• Richardson ES, Pitt WG, Woodbury DJ. The role of cavitation in liposome formation. Biophys J. 2007;93(12):4100–4107.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Pardakhty A, Hajhashemi V-i, et al. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv. 2003;10(4):251–262.
   PubMed Web of Science ®Google Scholar
• Lee S-C, Lee K-E, Kim J-J, et al. The effect of cholesterol in the liposome bilayer on the stabilization of incorporated retinol. J Liposome Res. 2005;15(3–4):157–166.
   PubMed Web of Science ®Google Scholar
• Cable C. An examination of the effect of surface modifications on the physicochemical and biological properties of non-ionic surfactant vesicles (surfactant vesicles, physicochemical properties) [dissertation]. University of Strathclyde; 1992.
   Google Scholar
• Moazeni E, Gilani K, Sotoudegan F, et al. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencapsul. 2010;27(7):618–627.
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Farghaly U, Moharram H. Effects of surfactant type and cholesterol level on niosomes physical properties and in vivo ocular performance using timolol maleate as a model drug. J Pharm Investig. 2014;44(5):329–337.
   Google Scholar
• Akbari V, Abedi D, Pardakhty A, et al. Release studies on ciprofloxacin loaded non-ionic surfactant vesicles. Avicenna J Med Biotechnol. 2015;7(2):69–75.
   PubMedGoogle Scholar
• Patel H. Liposomes: a practical approach. Oxford: RRC New; Oxford University Press; 1990. 301 pp.; £22.50.
   Google Scholar
• Gupta M, Vaidya B, Mishra N, et al. Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery. Artif Cells Blood Substit Immobil Biotechnol. 2011;39(6):376–384.
   PubMed Web of Science ®Google Scholar
• Marwa A, Omaima S, Hanaa E-G, et al. Preparation and in-vitro evaluation of diclofenac sodium niosomal formulations. Int J Pharm Sci Res. 2013;4(5):1757.
   Google Scholar
• Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172(1–2):33–70.
   Web of Science ®Google Scholar
• Khazaeli P, Pardakhty A, Shoorabi H. Caffeine-loaded niosomes: characterization and in vitro release studies. Drug Deliv. 2007;14(7):447–452.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J Pharm. 1994;105(1):1–6.
   Web of Science ®Google Scholar
• Hao Y, Zhao F, Li N, et al. Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm. 2002;244(1–2):73–80.
   PubMed Web of Science ®Google Scholar
• Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B. 2011;1(4):208–219.
   Web of Science ®Google Scholar
• Chaw CS, Ah Kim KY. Effect of formulation compositions on niosomal preparations. Pharm Dev Technol. 2013;18(3):667–672.
   PubMed Web of Science ®Google Scholar
• Junyaprasert VB, Singhsa P, Suksiriworapong J, et al. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Int J Pharm. 2012;423(2):303–311.
   PubMed Web of Science ®Google Scholar
• Mokhtar M, Sammour OA, Hammad MA, et al. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm. 2008;361(1–2):104–111.
   PubMed Web of Science ®Google Scholar
• Sadeghi S, Bakhshandeh H, Cohan RA, et al. Synergistic anti-staphylococcal activity of niosomal recombinant lysostaphin-LL-37. Int J Nanomedicine. 2019;14:9777–9792.
   PubMed Web of Science ®Google Scholar
• Barani M, Mirzaei M, Torkzadeh-Mahani M, et al. Lawsone-loaded Niosome and its antitumor activity in MCF-7 breast cancer cell line: a nano-herbal treatment for cancer. Daru. 2018;26(1):11–17.
   PubMed Web of Science ®Google Scholar
• Hajizadeh MR, Maleki H, Barani M, et al. In vitro cytotoxicity assay of d-limonene niosomes: an efficient nano-carrier for enhancing solubility of plant-extracted agents. Res Pharm Sci. 2019;14(5):448–458.
   PubMed Web of Science ®Google Scholar
• Alemi A, Reza JZ, Haghiralsadat F, et al. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy. J Nanobiotechnol. 2018;16(1):28.
   PubMed Web of Science ®Google Scholar
• Manosroi A, Bauer K. The entrapment of a human insulin–DEAE dextran complex in different compound liposomes. Drug Dev Ind Pharm. 1989;15(14–16):2531–2546.
   Web of Science ®Google Scholar
• Akbarzadeh I, Yaraki MT, Bourbour M, et al. Optimized doxycycline-loaded niosomal formulation for treatment of infection-associated prostate cancer: an in-vitro investigation. J Drug Deliv Sci Technol. 2020;57:101715.
   Web of Science ®Google Scholar
• El-Ridy MS, Yehia SA, Mohsen AM, et al. Formulation of niosomal gel for enhanced transdermal lornoxicam delivery: in-vitro and in-vivo evaluation. Curr Drug Deliv. 2018;15(1):122–133.
   PubMed Web of Science ®Google Scholar
• Weiner AL. Liposomes as carriers for polypeptides. Adv Drug Deliv Rev. 1989;3(3):307–341.
   Google Scholar
• Weiner N, Williams N, Birch G, et al. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model. Antimicrob Agents Chemother. 1989;33(8):1217–1221.
   PubMed Web of Science ®Google Scholar
• Pardakhty A, Moazeni E, Varshosaz J, et al. Pharmacokinetic study of niosome-loaded insulin in diabetic rats. Daru. 2011;19(6):404.
   PubMed Web of Science ®Google Scholar
• Balasubramaniam A, Anil Kumar V, Sadasivan Pillai K. Formulation and in vivo evaluation of niosome-encapsulated daunorubicin hydrochloride. Drug Dev Ind Pharm. 2002;28(10):1181–1193.
   PubMed Web of Science ®Google Scholar
• Zidan AS, Hosny KM, Ahmed OA, et al. Assessment of simvastatin niosomes for pediatric transdermal drug delivery. Drug Deliv. 2016;23(5):1536–1549.
   PubMed Web of Science ®Google Scholar
• Lawrence M, Chauhan S, Lawrence S, et al. The formation, characterization and stability of non-ionic surfactant vesicles. STP Pharma Sci. 1996;6(1):49–60.
   Google Scholar
• Seras-Cansell M, Ollivon M, Lesieur S. Generation of non-ionic monoalkyl amphiphile-cholesterol vesicles: evidence of membrane impermeability to octyl glucoside. STP Pharma Sci. 1996;6(1):12–20.
   Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.
   PubMed Web of Science ®Google Scholar
• Leibowitz B, Yu J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther. 2010;9(6):417–422.
   PubMed Web of Science ®Google Scholar
• Wood WG, Igbavboa U, Muller WE, et al. Statins, Bcl-2, and apoptosis: cell death or cell protection? Mol Neurobiol. 2013;48(2):308–314.
   PubMed Web of Science ®Google Scholar
• Yoon O, Roh J. Downregulation of KLF4 and the Bcl-2/Bax ratio in advanced epithelial ovarian cancer. Oncol Lett. 2012;4(5):1033–1036.
   PubMed Web of Science ®Google Scholar
• Hemann M, Lowe S. The p53–Bcl-2 connection. Cell Death Differ. 2006;13(8):1256–1259.
   Google Scholar
• Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta. 2009;1787(5):414–420.
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2(8):594–604.
   PubMed Web of Science ®Google Scholar
• Spampanato C, De Maria S, Sarnataro M, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene BCL-2 gene expression. Int J Oncol. 2012;40(4):935–941.
   PubMed Web of Science ®Google Scholar
• Costanzo M, Carton F, Marengo A, et al. Fluorescence and electron microscopy to visualize the intracellular fate of nanoparticles for drug delivery. Eur J Histochem. 2016;60(2):2640.
   PubMed Web of Science ®Google Scholar
• Malatesta M, Giagnacovo M, Costanzo M, et al. Diaminobenzidine photoconversion is a suitable tool for tracking the intracellular location of fluorescently labelled nanoparticles at transmission electron microscopy. Eur J Histochem. 2012;56(2):20.
   Web of Science ®Google Scholar
• Varkouhi AK, Scholte M, Storm G, et al. Endosomal escape pathways for delivery of biologicals. J Control Release. 2011;151(3):220–228.
   PubMed Web of Science ®Google Scholar
• Xia X-X, Wang M, Lin Y, et al. Hydrophobic drug-triggered self-assembly of nanoparticles from silk-elastin-like protein polymers for drug delivery. Biomacromolecules. 2014;15(3):908–914.
   PubMed Web of Science ®Google Scholar
• Amiri B, Ebrahimi-Far M, Saffari Z, et al. Preparation, characterization and cytotoxicity of silibinin-containing nanoniosomes in T47D human breast carcinoma cells. Asian Pac J Cancer Prev. 2016;17(8):3835–3838.
   PubMedGoogle Scholar
• Kanaani L, Javadi I, Ebrahimifar M, et al. Effects of cisplatin-loaded niosomal nanoparticles on BT-20 human breast carcinoma cells. Asian Pac J Cancer Prev. 2017;18(2):365–368.
   PubMedGoogle Scholar
• Nazari-Vanani R, Karimian K, Azarpira N, et al. Capecitabine-loaded nanoniosomes and evaluation of anticancer efficacy. Artif Cells Nanomed Biotechnol. 2019;47(1):420–426.
   PubMed Web of Science ®Google Scholar
• Amiri B, Ahmadvand H, Farhadi A, et al. Delivery of vinblastine-containing niosomes results in potent in vitro/in vivo cytotoxicity on tumor cells. Drug Dev Ind Pharm. 2018;44(8):1371–1376.
   PubMed Web of Science ®Google Scholar
• Sezgin-Bayindir Z, Onay-Besikci A, Vural N, et al. Niosomes encapsulating paclitaxel for oral bioavailability enhancement: preparation, characterization, pharmacokinetics and biodistribution. J Microencapsul. 2013;30(8):796–804.
   PubMed Web of Science ®Google Scholar